Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Genetic Testing Raises Complex Legal, Ethical, Social Issues

July 1, 1999
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 7
Volume 8
Issue 7

BALTIMORE-“However unfamiliar the territory, physicians, nurses, and other health care providers must understand the murky region surrounding genetic testing where legal, ethical, and social questions overlap science,” said Karen H. Rothenberg, JD, MPA, director of the Law and Health Care Program, University of Maryland School of Law. She spoke at a program on clinical cancer genetics held at Johns Hopkins University.

BALTIMORE—“However unfamiliar the territory, physicians, nurses, and other health care providers must understand the murky region surrounding genetic testing where legal, ethical, and social questions overlap science,” said Karen H. Rothenberg, JD, MPA, director of the Law and Health Care Program, University of Maryland School of Law. She spoke at a program on clinical cancer genetics held at Johns Hopkins University.

“Genetic testing produces data different from other kinds of medical information,” Ms. Rothenberg said. She referred to the distinctions as the “six P’s” (see Table ). Genetic information, she said, is “personal, powerful, potentially predictive, pedigree sensitive, permanent, and prejudicial.”

The Six P’s of Genetic Information

Genetic Information Is:

Personal (as unique as an individual’s DNA)

Powerful (or may appear to be)

Potentially predictive (of future health problems)

Pedigree sensitive (it is not just about individuals, but about their families, who may not want the information)

Permanent (currently, or at least not easily changed by gene therapy)

Prejudicial (historically used to discriminate against populations)

Legal issues that may crop up when dealing with genetic testing include informed consent, discrimination, privacy, liability, and family rights. She provided specific examples and advice on how to avoid potential legal problems.

 Informed consent has its benefits and risks, but its context is constantly changing, she said. For instance, the predictive value of a genetic test may not be known or may have varying usefulness in diagnosis. There is a risk of misinterpretation among patients or in the community, or there may be limited data on the effectiveness of preventive or interventional strategies.

 The effect on health behavior may not always be straightforward. Would a hypothetical test for lung cancer susceptibility, for example, empower or paralyze people? Would a negative test free people from the fear of lung cancer and so encourage them to smoke—leading to other smoking-related illnesses?

“There is great difficulty in quantifying social risk,” Ms. Rothenberg said. “Much depends on patients’ personal histories. The views of two people may differ depending on whether they see themselves as ‘healthy’ or a cancer patient.”

 Legal prohibitions on genetic discrimination in health insurance have been proposed and passed in some states, she said. Generally, these have stated that insurance companies may not require or request genetic tests, may not ask for results, may not base coverage or benefits on genetic testing, and may not consider genetic testing in determining rates.

While these laws were enacted to protect consumers, they share a number of problems. “Most focus on test results, but say nothing of family history or other sources of information,” she said (although a new Maryland law covers this point). “Half the people in the United States get their health insurance under ERISA, which is not included under state legal protection, so we need a federal solution. Now we’re trying to educate Congress so we can reap the benefit of the Human Genome Project.”

The federal Health Insurance Portability and Accountability Act (HIPAA, or the Kennedy-Kassebaum Act) states that genetic information cannot be considered a pre-existing condition, nor can it be used to determine insurance eligibility. But the bill says nothing about genetic privacy rights or about the practice of requesting genetic testing as a condition of medical coverage.

On the other hand, the Equal Employment Opportunity Commission has interpreted the Americans with Disability Act to say that a disability may be created on the basis of genetic information, citing predisposition to colon cancer as an example. However, this interpretation has not yet been tested in the courts.

“Thus we need a federal law saying that employers cannot discriminate on the basis of genetic information,” Ms. Rothenberg said. Congress might decide to deal with employment and health insurance issues together or by specific genetic legislation on each topic.

Family issues. “Perhaps the most complex questions arise not in Congress,” Ms. Rothenberg said, “but at the intersection of medical knowledge, ethical issues, and family dynamics.” The individual autonomy model that is a part of contemporary medical ethics “crumbles when testing genetics,” she said. “The family is the unit under discussion, not the individual.”

Both patients and their families may believe they have a right to know the outcome of genetic tests—and a right not to know, as well. Genetic information can throw a harsh light onto social and genetic relationships and intergenerational issues. Expectations of privacy may vary widely, and laws generally do not specifically immunize health care providers against lawsuits based on their giving or not giving genetic information.

“We value information in the health care system,” she said. “Doctors, genetic counselors, and nurses have to do good risk assessment with patients and then maintain good communication with their families when that is desired.”

Deciding on genetic testing for children depends on the disease and on the test. Children aren’t ordinarily tested for adult-onset diseases until they reach majority status. “Parental anxiety is not sufficient reason to test,” she said, although there may be a few cases in which medical benefits outweigh psychological harm.

“But there are professionals who believe it is medically appropriate to offer genetic testing if you are looking for a childhood disease, there is an effective intervention, and the test can be adequately interpreted,” she said.

Genetic information is already a part of family law and the court system. “When people fight each other in court, they want to win,” she said, and that means bringing any available evidence.

Besides the obvious area of paternity, Ms. Rothenberg said, genetic testing might be dragged into custody battles in divorce trials. “Could a mother with a mutation predisposing her to breast cancer, for example, be denied custody of her children because the father believes he will live longer?” she hypothesized. A court might rule it would be in “the best interest of the child” to live with the parent who did not have a genetic predisposition to disease.

Finally, Ms. Rothenberg asked, “how can law support health care providers in taking the right steps in the age of genetic information?” She gave this advice:

Disclose to patients the benefits, risks, and limitations of genetic testing. “Studies have show that if something goes wrong in the operating room, the patient is more likely to sue if prior communication was lacking,” she said.

Follow up and stay in contact with the patient after genetic testing. Establish and maintain a working doctor-patient relationship.

Maintain confidentiality.

Be aware of the risk to others of genetic information and talk to patients about those issues.

Anticipate potential legal, ethical, and social issues before testing.

Understand the dynamics of the patient’s family. Encourage family involvement but be aware of potential problems.

Avoid coercion by the patient’s family or by other health care providers to reveal test results.

Be aware of applicable state and federal laws.

Articles in this issue

Nasal Angiogenesis Inhibitor May Stop Kaposi’s Sarcoma
Surgeon’s Perspective on Neoadjuvant Chemo for Breast Cancer
STAR Breast Cancer Prevention Trial Begins Enrollment
Studies Suggest New Approaches in Hereditary Ovarian Cancer
Lycopene Beneficial in Prostate Cancer
Komen Launches REMEMBER
Advice and Support for Daughters of Breast Cancer Patients
Fetus May Be Harmed by Second-Hand Smoke
Genes Linked to Smoking Affinity, Smoking-Induced Lung Cancer
Ultraviolet Light Slated for Review as Carcinogen
NCI Funding Complementary/Alternative Medicine Trials
COX2 Inhibitors Promising in Prevention
Colon Cancer Cases Show Dilemmas of Genetic Testing
Vitamin Supplementation Appears to Protect Against p53 Mutations
Genetic Testing Raises Complex Legal, Ethical, Social Issues
Recent Videos
Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
2 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.
Extended follow-up for individuals with H3 K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.
Related Content
Advertisement

Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.

Dordaviprone Offers “Exciting” Option for Diffuse Midline Glioma Population

Roman Fabbricatore
August 21st 2025
Article

Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.


Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 18th 2025
Podcast

Daniel C. McFarland, DO, and Michelle Fingeret, PhD, discuss the issue of body image in patients with cancer.


Previously, TTFields was granted approval by the FDA in previously treated metastatic NSCLC.

Developer Submits Premarket Approval Application for TTFields in Pancreatic Cancer

Tim Cortese
August 21st 2025
Article

TTFields plus chemotherapy significantly prolonged overall survival compared with chemotherapy alone in patients with pancreatic cancer.


Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 14th 2025
Podcast

The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.


Perceptions of Dermatologic AEs Could Impact Treatment Adherence

Perceptions of Dermatologic AEs Could Impact Treatment Adherence

Ariana Pelosci
August 21st 2025
Article

A survey found that patients believed dermatologic AEs were more prevalent with anti-cancer therapies than what has been reported.


Induction chemotherapy may allow investigators to biologically select patients with a favorable prognosis who benefit most from chemoradiotherapy.

Chemoradiation May Convert Unresectable Pancreatic Cancers for Resection

Russ Conroy
August 20th 2025
Article
Related Content
Advertisement

Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.

Dordaviprone Offers “Exciting” Option for Diffuse Midline Glioma Population

Roman Fabbricatore
August 21st 2025
Article

Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.


Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 18th 2025
Podcast

Daniel C. McFarland, DO, and Michelle Fingeret, PhD, discuss the issue of body image in patients with cancer.


Previously, TTFields was granted approval by the FDA in previously treated metastatic NSCLC.

Developer Submits Premarket Approval Application for TTFields in Pancreatic Cancer

Tim Cortese
August 21st 2025
Article

TTFields plus chemotherapy significantly prolonged overall survival compared with chemotherapy alone in patients with pancreatic cancer.


Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 14th 2025
Podcast

The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.


Perceptions of Dermatologic AEs Could Impact Treatment Adherence

Perceptions of Dermatologic AEs Could Impact Treatment Adherence

Ariana Pelosci
August 21st 2025
Article

A survey found that patients believed dermatologic AEs were more prevalent with anti-cancer therapies than what has been reported.


Induction chemotherapy may allow investigators to biologically select patients with a favorable prognosis who benefit most from chemoradiotherapy.

Chemoradiation May Convert Unresectable Pancreatic Cancers for Resection

Russ Conroy
August 20th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.